Last updated: August 1, 2026
Orilissa, the brand name for elagolix, is an oral, nonpeptide gonadotropin-releasing hormone antagonist marketed by AbbVie for endometriosis-associated pain. The drug received FDA approval in July 2018. Its clinical value rests on rapid suppression of ovarian hormone production without the injectable administration required for older GnRH therapies.[1]
Orilissa remains commercially relevant in endometriosis, but its long-term growth is constrained by dose-duration limits, bone-mineral-density warnings, competition from hormonal contraceptives and progestins, and eventual generic exposure. AbbVie’s broader elagolix franchise also includes Oriahnn, a fixed-dose elagolix/estradiol/norethindrone product approved for heavy menstrual bleeding associated with uterine fibroids.[2]
What is Orilissa and how does elagolix work?
Orilissa contains elagolix sodium, a small-molecule GnRH receptor antagonist. It suppresses luteinizing hormone and follicle-stimulating hormone, reducing ovarian estradiol and progesterone production.
The FDA-approved dosage options are:
| Dose |
Primary use |
Maximum treatment duration |
| 150 mg once daily |
Moderate endometriosis-associated pain |
24 months |
| 200 mg twice daily |
Severe endometriosis-associated pain |
6 months |
The 200 mg twice-daily dose produces greater estradiol suppression and has a shorter permitted treatment duration because of increased bone-loss risk. Orilissa is contraindicated in pregnancy, osteoporosis, severe hepatic impairment, and certain drug-interaction settings.[1]
What clinical trials supported Orilissa approval?
The FDA approval relied primarily on the EM-1 and EM-2 Phase III trials, which evaluated elagolix in women with moderate-to-severe endometriosis-associated pain.
EM-1 and EM-2 Phase III trials
The two pivotal studies were randomized, double-blind, placebo-controlled trials. Their principal endpoints measured clinically meaningful reductions in dysmenorrhea and non-menstrual pelvic pain without requiring rescue analgesics.
Across the pivotal program:
- The 150 mg once-daily dose reduced dysmenorrhea and non-menstrual pelvic pain compared with placebo.
- The 200 mg twice-daily dose produced greater pain reduction than the lower dose.
- Improvements appeared within the first months of therapy.
- Hot flushes, headache, nausea, mood changes and reduced bone mineral density were the main tolerability concerns.
- Amenorrhea and irregular bleeding were common pharmacologic effects.
The clinical program showed that Orilissa can reduce pain without surgery or depot injection. It did not establish that elagolix eliminates endometriotic lesions or permanently changes disease progression.[3]
Long-term extension studies
Extension studies evaluated continued treatment after the pivotal trials. These studies supported the dose-duration limits included in the label and monitored bone mineral density, vasomotor symptoms, lipid changes and menstrual suppression.
The key long-term limitation is cumulative skeletal exposure. Bone loss may not fully reverse after treatment, and the label limits duration based on dose. This restriction reduces the drug’s utility as a continuous long-term therapy for younger patients who may require treatment for many years.[1]
Current clinical-trial position
The principal efficacy question for Orilissa has been resolved through completed Phase III development. The commercial clinical focus has shifted from initial approval to:
- Long-term safety surveillance.
- Real-world persistence and treatment sequencing.
- Use in patients who have failed oral contraceptives or progestins.
- Evaluation of add-back hormonal strategies.
- Comparisons with newer oral GnRH antagonists.
- Research into endometriosis diagnosis, recurrence and postoperative management.
Orilissa does not have an approved indication for infertility, uterine fibroids, adenomyosis or general pelvic pain without an endometriosis diagnosis.
How does Orilissa compare with competing endometriosis drugs?
Orilissa competes with hormonal contraceptives, progestins, danazol, injectable GnRH agonists and newer oral GnRH antagonists.
| Product |
Active ingredient |
Administration |
Endometriosis position |
Main commercial issue |
| Orilissa |
Elagolix |
Oral tablet |
Approved for endometriosis pain |
Bone loss and duration limits |
| Myfembree |
Relugolix/estradiol/norethindrone |
Oral tablet |
Approved for endometriosis pain and fibroid bleeding |
Competes directly in oral GnRH therapy |
| Lupron Depot |
Leuprolide |
Injection |
Established GnRH agonist use |
Injection burden and hypoestrogenic effects |
| Nataxin and generic progestins |
Various |
Oral or injectable |
Common first-line hormonal treatment |
Low cost and broad availability |
| Danazol |
Danazol |
Oral |
Older endometriosis therapy |
Androgenic adverse effects |
| Visanne and other dienogest products |
Dienogest |
Oral |
Widely used outside the U.S. |
International and generic competition |
Myfembree presents the most direct branded threat because it offers oral GnRH antagonism with add-back hormones. Its regimen is designed to reduce hypoestrogenic adverse effects and support longer treatment in appropriate patients. Orilissa retains an advantage when clinicians want dose flexibility or do not want immediate estrogen/progestin add-back therapy.[4]
What FDA exclusivity does Orilissa have?
Orilissa received FDA approval on July 24, 2018. The approval did not rely on biologic exclusivity because elagolix is a conventional small molecule.[1]
The primary FDA regulatory protections were:
- Five-year new chemical entity exclusivity from approval.
- Orphan-drug exclusivity was not the basis of the endometriosis approval.
- Patent protection covering elagolix and related pharmaceutical claims.
- Regulatory exclusivity associated with pediatric studies may apply if FDA requirements were completed, but the principal commercial issue is patent and generic litigation exposure.
Five-year NCE exclusivity would have prevented an ANDA submission containing a Paragraph IV certification before July 2023, subject to statutory exceptions. The first generic applicant could receive 180-day exclusivity if it successfully qualifies under the first-filer rules.
What patents protect Orilissa?
Orilissa protection is based on a patent family covering elagolix, pharmaceutical compositions, and use of GnRH antagonists. The relevant protection is separate from the FDA label and must be evaluated by claim scope, patent listing, terminal disclaimers, prosecution history and litigation outcomes.
Patent categories
| Protection category |
Commercial purpose |
| Active-ingredient patents |
Protect elagolix or related chemical genus claims |
| Composition patents |
Cover tablet formulations and pharmaceutical compositions |
| Method-of-use patents |
Cover treatment of endometriosis-associated pain |
| Dose-regimen claims |
Protect once-daily and twice-daily administration |
| Manufacturing patents |
May restrict practical production routes or intermediates |
| Combination patents |
More relevant to elagolix add-back products such as Oriahnn |
The core composition estate is more important than formulation protection because generic applicants can often design around narrow tablet or excipient claims. Method-of-use patents can delay some commercial indications but generally do not prevent all generic sales if a label can be carved out.
The effective patent term can extend beyond the nominal expiration date through patent-term adjustment or patent-term extension, but only within statutory limits. Orange Book-listed patents, expiration dates and any pediatric extension should be confirmed against the current FDA Orange Book and USPTO records before a launch decision.[5][6]
What is the Orange Book status of Orilissa?
Orilissa is an FDA-approved small-molecule prescription product and is eligible for ANDA competition. Its Orange Book status depends on the patents listed for the specific strengths and dosage forms.
The practical Orange Book questions are:
- Which patents are listed against the 150 mg and 200 mg tablets?
- Do the listings cover the active ingredient, formulation or method of use?
- Which patents remain unexpired?
- Has AbbVie submitted any patent-listing corrections or delistings?
- Have generic applicants filed Paragraph IV certifications?
- Has any applicant received a 30-month stay through patent litigation?
An ANDA applicant may file:
- Paragraph I, stating no patent is listed.
- Paragraph II, stating the patent has expired.
- Paragraph III, accepting delayed approval until patent expiration.
- Paragraph IV, asserting that the patent is invalid, unenforceable or not infringed.
- A section viii statement carving out a patented method of use.
Which companies are challenging Orilissa patents?
Publicly disclosed generic challengers and litigation activity should be assessed through FDA ANDA records, district-court dockets and AbbVie’s securities filings. The principal competitive threat is from generic pharmaceutical companies with experience in hormonal products and complex oral therapies.
Potential entrants are likely to include large generic manufacturers such as Teva, Sandoz, Viatris, Lupin, Zydus, Dr. Reddy’s and Sun Pharma, although an applicant’s actual filing cannot be inferred from market participation alone.
For Orilissa, the likely litigation sequence is:
- ANDA submission with a Paragraph IV certification.
- Notice letter to AbbVie.
- Patent-infringement action within 45 days.
- Potential 30-month FDA approval stay.
- Settlement, judgment or at-risk launch.
- Generic entry after patent resolution or statutory expiration.
No biosimilar pathway applies because elagolix is not a biologic. Generic competition would proceed under the ANDA pathway.
What generic entry risks exist for Orilissa?
Orilissa faces medium-to-high long-term generic risk. The drug has characteristics that support generic substitution:
- Small-molecule active ingredient.
- Oral immediate-release tablet.
- Straightforward pharmacologic mechanism.
- Established FDA safety database.
- No biologic manufacturing barrier.
- No required injection device.
- Potentially manageable bioequivalence program.
Barriers remain for:
- Controlled manufacturing of the active ingredient.
- Demonstrating bioequivalence for each strength.
- Patent claims covering the active ingredient or dosage regimen.
- Commercial access to managed-care formularies.
- Limited market size relative to high-volume chronic drugs.
- Physician concerns about bone safety and patient selection.
Generic entry is more likely to produce rapid price erosion in the 150 mg strength. The 200 mg twice-daily strength may retain some price segmentation if its use remains concentrated among patients with severe disease.
What patent litigation affects Orilissa?
The most important litigation risk is any AbbVie action following a Paragraph IV challenge to an Orange Book-listed patent. The economic significance depends on whether the challenged patent covers:
- Elagolix itself.
- Both approved strengths.
- The commercial endometriosis indication.
- A narrow regimen that can be carved out.
- A formulation that is difficult to avoid.
A composition patent covering the active ingredient usually creates a stronger barrier than a method-of-use patent. A narrow indication patent may permit a generic launch with a skinny label, leaving branded sales protected only for the patented use.
Settlement agreements could provide a fixed generic entry date, an authorized generic arrangement or a license with restrictions. AbbVie’s annual reports and SEC filings are the principal sources for material settlements and litigation reserves.[7]
Does Oriahnn strengthen or weaken the Orilissa franchise?
Oriahnn broadens AbbVie’s elagolix platform but does not remove Orilissa’s core limitations. Oriahnn combines elagolix with estradiol and norethindrone acetate, reducing hypoestrogenic effects while introducing estrogen-related warnings and contraindications.[2]
| Factor |
Orilissa |
Oriahnn |
| Active regimen |
Elagolix alone |
Elagolix with add-back hormones |
| Primary indication |
Endometriosis pain |
Heavy menstrual bleeding from fibroids |
| Treatment duration |
Six or 24 months depending on dose |
Limited duration under labeling |
| Main safety concern |
Bone loss and hypoestrogenic symptoms |
Thromboembolic and estrogen-related risk |
| Generic complexity |
Single-drug oral product |
Fixed-dose combination |
| Franchise effect |
Core endometriosis product |
Expands elagolix commercial reach |
The two products may compete for some prescribers and payer resources, but they address different disease settings. Oriahnn’s combination formulation creates a distinct patent and regulatory profile rather than simply extending Orilissa’s endometriosis protection.
What is Orilissa’s market size and revenue outlook?
Orilissa’s market is driven by diagnosed endometriosis, specialist prescribing, prior failure of contraceptives or progestins, and payer coverage. The addressable patient population is large, but the treated branded market is narrower because many patients use low-cost hormonal therapies or undergo surgery.
Commercial drivers
- High prevalence of endometriosis among reproductive-age women.
- Delayed diagnosis and undertreatment.
- Demand for non-surgical pain control.
- Oral administration and rapid onset.
- Specialist adoption in gynecology.
- Use after inadequate response to first-line hormonal therapy.
Commercial constraints
- Treatment-duration limits.
- Bone-density monitoring.
- Hot flushes and mood-related adverse events.
- Generic alternatives to first-line hormonal therapy.
- Competition from Myfembree.
- Payer utilization management.
- Potential long-term generic erosion.
Projection scenario
The following scenario is an analytical estimate for Orilissa product revenue, not AbbVie-reported guidance.
| Year |
Base-case revenue index, 2024 = 100 |
Market interpretation |
| 2024 |
100 |
Mature branded product |
| 2025 |
96 |
Stable demand offset by competitor pressure |
| 2026 |
91 |
Greater oral GnRH competition |
| 2027 |
84 |
Pre-generic erosion or settlement uncertainty |
| 2028 |
68 |
Possible first generic impact |
| 2029 |
45 |
Accelerating price and volume substitution |
| 2030 |
30 |
Mature generic market |
Under this scenario, Orilissa remains a meaningful specialty product through the late 2020s but does not become a major growth engine for AbbVie. A favorable patent outcome or delayed generic entry could preserve branded revenue longer. An early settlement could cause a sharp decline before nominal patent expiry.
A reasonable market framework is:
- Bear case: generic entry before or near 2028, with 60% to 80% revenue erosion within two years.
- Base case: generic entry around 2028-2029, with 50% to 70% erosion over two years.
- Bull case: effective patent protection through 2030 or later, with gradual decline from branded competition rather than immediate substitution.
How strong is the Orilissa patent estate?
The estate is commercially strongest if AbbVie maintains enforceable claims covering elagolix itself or a broad, difficult-to-design-around use. It is weaker when protection depends on narrow dosage or indication claims.
Strength assessment
| Patent issue |
Assessment |
| Active ingredient |
Potentially strong if an unexpired composition claim remains enforceable |
| Tablet formulation |
Moderate unless the formulation is technically difficult to replicate |
| Method of use |
Moderate to weak against skinny-label entry |
| Dose regimen |
Moderate; vulnerable to alternative dosing or label carve-outs |
| Manufacturing process |
Variable; relevant only if alternatives are impractical |
| Biosimilar protection |
Not applicable |
| Generic substitution risk |
Material after patent barriers fall |
The main diligence point is claim coverage, not the number of listed patents. A large patent family can provide limited protection if the claims overlap narrowly or expire together.
What generic launch scenarios should investors consider?
Three launch scenarios matter.
Delayed full-label launch
A generic company waits for patent expiration or loses litigation. It launches with an endometriosis label and competes directly across both strengths. This scenario produces the fastest substitution.
Skinny-label launch
The applicant carves out patented methods of use but retains non-patented indications or dosing information. This can permit entry while leaving some branded use protected. For Orilissa, the commercial impact depends on whether the carved-out label still supports broad physician prescribing.
At-risk launch
A generic launches before final patent resolution after obtaining approval. AbbVie may seek damages, an injunction or other remedies. This scenario creates high litigation exposure but can accelerate market disruption if the generic company prevails.
What geographic markets affect Orilissa?
The United States is the principal market for the Orilissa brand and the main source of patent-based launch risk. International markets use different regulatory names, reimbursement systems and patent terms.
Geographic considerations include:
- U.S. ANDA litigation and Orange Book listings.
- European national or centralized regulatory pathways.
- Country-specific patent term adjustments.
- Local compulsory licensing and patent opposition rules.
- Different adoption of dienogest and GnRH therapies.
- Variable reimbursement for endometriosis treatment.
- Parallel trade and local generic manufacturing.
A U.S. generic launch does not automatically establish launch rights in Europe, Japan, Canada or emerging markets. Each jurisdiction requires separate patent and regulatory analysis.
Key Takeaways
- Orilissa is an approved oral elagolix product for moderate-to-severe endometriosis-associated pain.
- The pivotal EM-1 and EM-2 trials established efficacy for dysmenorrhea and non-menstrual pelvic pain.
- The 150 mg once-daily dose has a 24-month treatment limit; the 200 mg twice-daily dose has a six-month limit.
- Myfembree is the principal branded oral GnRH antagonist competitor.
- Orilissa is a small molecule and faces generic, not biosimilar, competition.
- Generic risk depends on the remaining Orange Book patents, Paragraph IV filings and any AbbVie settlement.
- A base-case model indicates declining branded revenue through the late 2020s, with sharper erosion after generic entry.
- Composition claims are more valuable than narrow formulation or method-of-use claims.
- Oriahnn expands AbbVie’s elagolix franchise into uterine-fibroid bleeding but has a separate indication and safety profile.
FAQs
When did the FDA approve Orilissa?
The FDA approved Orilissa on July 24, 2018, for moderate-to-severe pain associated with endometriosis.[1]
Is Orilissa the same drug as Myfembree?
No. Both contain a GnRH antagonist, but Orilissa contains elagolix alone, while Myfembree contains relugolix with estradiol and norethindrone acetate.
Can Orilissa be used indefinitely?
No. FDA labeling limits treatment to 24 months for 150 mg once daily and six months for 200 mg twice daily because of bone-mineral-density loss and related safety concerns.[1]
Does Orilissa have biosimilar competition?
No. Elagolix is a small molecule. Competitors would file ANDAs for generic approval rather than abbreviated biologics applications.
What is the main investment risk for Orilissa?
The main risk is loss of exclusivity through a Paragraph IV challenge, patent settlement or patent expiration, followed by rapid generic price erosion in a market with several established hormonal alternatives.
References
- U.S. Food and Drug Administration. (2024). Orilissa (elagolix) prescribing information.
- U.S. Food and Drug Administration. (2024). Oriahnn (elagolix, estradiol, and norethindrone acetate) prescribing information.
- Taylor, H. S., Giudice, L. C., Lessey, B. A., et al. (2017). Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. New England Journal of Medicine, 377(1), 28-40.
- U.S. Food and Drug Administration. (2021). Myfembree (relugolix, estradiol, and norethindrone acetate) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension records.
- AbbVie Inc. (2024). Annual report and Form 10-K.
